Zimbabwe has rejected a substantial American healthcare agreement valued at $367m (272 million pounds) spanning five years due to Washington's insistence on confidential information.
This rejection was revealed following a government memo dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "unbalanced".
An official representative later clarified that the US was requesting biological samples for research and commercial purposes while was unwilling to guarantee the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate process of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged continued talks to secure a agreement suitable to all parties so the country's critical HIV programme can continue.
Broader Context
This rejection follows a comparable case in Kenya, where a high court halted a related health funding agreement after concerns were raised about the security of citizens' health data.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
Based on statements, 16 nations in Africa have to date signed similar health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently on HIV treatment through American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data indefinitely, with no corresponding promise of access to any medical innovations – such as new medicines or tests – that could result from that provided information," his statement read.
"Effectively, our nation would provide the basic resources for scientific discovery without any assurance that the resulting innovations would be available to our citizens if a new disease outbreak emerge."
Sovereignty and Global Health
He also said that the American exit from the global health body and its push of bilateral deals were upending frameworks previously set up through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This mechanism is designed to guarantee that when a country contributes its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how future collaboration could be arranged in a way that honours the sovereignty and dignity of each country."
Health Experts Reaction
Medical experts said it recognised the official position, but recommended that negotiations must proceed since a large portion of the country's Aids initiatives were funded by foreign aid.
"Where technical issues arise, such as those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group said.
This impasse underscores the ongoing challenges between receiving crucial international aid and protecting local interests in an increasingly data-driven world.